David R Gandara

18PUBLICATIONS

142CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersChemotherapy

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (18)

Sort by Publication Date:

|Jun 03, 2026

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

|Mar 11, 2026

Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.

David R Gandara, Mahmut Gümüş, Saadettin Kilickap

|Jul 07, 2025

Authors response to "Letter to the Editor": "Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types".

Ryon P Graf, David R Gandara

|Jun 17, 2025

Costs and Benefits of Whole-Exome, Whole-Transcriptome Sequencing in Patients With Advanced Non-Small Cell Lung Cancer.

Jesse D Ortendahl, Gebra Cuyun Carter, Snehal G Thakkar

|Jun 04, 2025

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study.

Philip C Mack, Mary W Redman, Hanna Tukachinsky

|Feb 06, 2025

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types.

David R Gandara, Neeraj Agarwal, Shilpa Gupta

Pageof 3

Frequent Collaborators

Mary W Redman

Karen Kelly

Philip C Mack

Roy S Herbst

Fred R Hirsch

Joel W Neal

Jonathan W Riess

Karen L Reckamp

Natasha B Leighl

Konstantin H Dragnev

Frequent Collaborators

Mary W Redman

Karen Kelly

Philip C Mack

Roy S Herbst